Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Compare

1,228 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CAPR Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Capricor

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CAPR Stock 12 Month Forecast

Average Price Target

$48.75

▲(75.30% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Capricor Therapeutics in the last 3 months. The average price target is $48.75 with a high forecast of $60.00 and a low forecast of $29.00. The average price target represents a 75.30% change from the last price of $27.81.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","19":"$19","33":"$33","47":"$47","61":"$61"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$48.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$29.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,19,33,47,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.65,10.753846153846155,14.857692307692309,18.961538461538463,23.065384615384616,27.169230769230772,31.27307692307693,35.37692307692308,39.48076923076923,43.58461538461539,47.688461538461546,51.792307692307695,55.89615384615385,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.65,9.888461538461538,13.126923076923077,16.365384615384613,19.603846153846156,22.842307692307692,26.080769230769228,29.31923076923077,32.55769230769231,35.79615384615385,39.034615384615385,42.27307692307692,45.51153846153846,{"y":48.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.65,8.36923076923077,10.088461538461539,11.807692307692308,13.526923076923078,15.246153846153847,16.965384615384615,18.684615384615384,20.403846153846153,22.123076923076923,23.842307692307692,25.56153846153846,27.28076923076923,{"y":29,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.45,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.38,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.21,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.33,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$48.75

Lowest Price Target$29.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Edward Tenthoff

Piper Sandler

$45

Buy

61.81%

Upside

Reiterated

12/17/25

Capricor Therapeutics (CAPR) Receives a Buy from Piper SandlerWe reiterate our Overweight rating and $45 price target.

Madison Elsaadi

B. Riley Securities

$21→$50

Buy

79.79%

Upside

Reiterated

12/15/25

Capricor Therapeutics price target raised to $50 from $21 at B. RileyCapricor Therapeutics price target raised to $50 from $21 at B. Riley

Leland Gershell

Oppenheimer

$22→$54

Buy

94.17%

Upside

Reiterated

12/08/25

Capricor Therapeutics price target raised to $54 from $22 at OppenheimerCapricor Therapeutics price target raised to $54 from $22 at Oppenheimer

Boobalan Pachaiyappan

Roth MKM

$22→$54

Buy

94.17%

Upside

Reiterated

12/08/25

Roth MKM Remains a Buy on Capricor Therapeutics (CAPR)

Jason McCarthy

Maxim Group

$25→$50

Buy

79.79%

Upside

Reiterated

12/04/25

Capricor Therapeutics price target raised to $50 from $25 at MaximCapricor Therapeutics price target raised to $50 from $25 at Maxim

Joseph Pantginis

H.C. Wainwright

$24→$60

Buy

115.75%

Upside

Reiterated

12/03/25

Capricor Therapeutics (CAPR) Receives a Buy from H.C. Wainwright

Matthew Venezia

Alliance Global Partners

$16→$48

Buy

72.60%

Upside

Reiterated

12/03/25

Alliance Global Partners Remains a Buy on Capricor Therapeutics (CAPR)

Catherine Novack

JonesTrading

$29

Buy

4.28%

Upside

Reiterated

09/25/25

Capricor approval on track for mid-2026, says JonesResearchCapricor approval on track for mid-2026, says JonesResearch

Kristen Kluska

Cantor Fitzgerald

$30→$22

Buy

-20.89%

Downside

Reiterated

07/11/25

Capricor Therapeutics price target lowered to $22 from $30 at Cantor FitzgeraldCapricor Therapeutics price target lowered to $22 from $30 at Cantor Fitzgerald

Aydin Huseynov

Ladenburg Thalmann & Co.

$48

Buy

72.60%

Upside

Reiterated

03/20/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Edward Tenthoff

Piper Sandler

$45

Buy

61.81%

Upside

Reiterated

12/17/25

Capricor Therapeutics (CAPR) Receives a Buy from Piper SandlerWe reiterate our Overweight rating and $45 price target.

Madison Elsaadi

B. Riley Securities

$21→$50

Buy

79.79%

Upside

Reiterated

12/15/25

Capricor Therapeutics price target raised to $50 from $21 at B. RileyCapricor Therapeutics price target raised to $50 from $21 at B. Riley

Leland Gershell

Oppenheimer

$22→$54

Buy

94.17%

Upside

Reiterated

12/08/25

Capricor Therapeutics price target raised to $54 from $22 at OppenheimerCapricor Therapeutics price target raised to $54 from $22 at Oppenheimer

Boobalan Pachaiyappan

Roth MKM

$22→$54

Buy

94.17%

Upside

Reiterated

12/08/25

Roth MKM Remains a Buy on Capricor Therapeutics (CAPR)

Jason McCarthy

Maxim Group

$25→$50

Buy

79.79%

Upside

Reiterated

12/04/25

Capricor Therapeutics price target raised to $50 from $25 at MaximCapricor Therapeutics price target raised to $50 from $25 at Maxim

Joseph Pantginis

H.C. Wainwright

$24→$60

Buy

115.75%

Upside

Reiterated

12/03/25

Capricor Therapeutics (CAPR) Receives a Buy from H.C. Wainwright

Matthew Venezia

Alliance Global Partners

$16→$48

Buy

72.60%

Upside

Reiterated

12/03/25

Alliance Global Partners Remains a Buy on Capricor Therapeutics (CAPR)

Catherine Novack

JonesTrading

$29

Buy

4.28%

Upside

Reiterated

09/25/25

Capricor approval on track for mid-2026, says JonesResearchCapricor approval on track for mid-2026, says JonesResearch

Kristen Kluska

Cantor Fitzgerald

$30→$22

Buy

-20.89%

Downside

Reiterated

07/11/25

Capricor Therapeutics price target lowered to $22 from $30 at Cantor FitzgeraldCapricor Therapeutics price target lowered to $22 from $30 at Cantor Fitzgerald

Aydin Huseynov

Ladenburg Thalmann & Co.

$48

Buy

72.60%

Upside

Reiterated

03/20/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Capricor Therapeutics

1 Month

xxx

Success Rate

5/9 ratings generated profit

Average Return

+63.89%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +63.89% per trade.

3 Months

xxx

Success Rate

4/9 ratings generated profit

Average Return

+46.16%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of +46.16% per trade.

1 Year

Jason McCarthyMaxim Group

Success Rate

14/15 ratings generated profit

Average Return

+145.12%

reiterated a buy rating 18 days ago

Copying Jason McCarthy's trades and holding each position for 1 Year would result in 93.33% of your transactions generating a profit, with an average return of +145.12% per trade.

2 Years

xxx

Success Rate

9/9 ratings generated profit

Average Return

+297.22%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +297.22% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CAPR Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CAPR has received 18 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. CAPR average Analyst price target in the past 3 months is 48.75.

Each month's total comprises the sum of three months' worth of ratings.

CAPR Financial Forecast

CAPR Earnings Forecast

Next quarter’s earnings estimate for CAPR is -$0.51 with a range of -$0.59 to -$0.28. The previous quarter’s EPS was -$0.54. CAPR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CAPR has Performed in-line its overall industry.

CAPR Sales Forecast

Next quarter’s sales forecast for CAPR is $525.00K with a range of $0.00 to $4.20M. The previous quarter’s sales results were $0.00. CAPR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CAPR has Performed in-line its overall industry.

CAPR Stock Forecast FAQ

What is CAPR’s average 12-month price target, according to analysts?

Based on analyst ratings, Capricor Therapeutics’s 12-month average price target is 48.75.

What is CAPR’s upside potential, based on the analysts’ average price target?

Capricor Therapeutics has 75.30% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CAPR a Buy, Sell or Hold?

Capricor Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Capricor Therapeutics’s price target?

The average price target for Capricor Therapeutics is 48.75. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $29.00. The average price target represents 75.30% Increase from the current price of $27.81.

What do analysts say about Capricor Therapeutics?

Capricor Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of CAPR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

CAPR Analyst Ratings

CAPR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Capricor Therapeutics

CAPR Analyst Recommendation Trends

CAPR Financial Forecast

CAPR Earnings Forecast

CAPR Sales Forecast

CAPR Stock Forecast FAQ

Detailed List of Analyst Forecasts